Last updated: August 25, 2025
Introduction
The patent DK2037922 pertains to a pharmaceutical innovation registered in Denmark. A comprehensive examination of its scope, claims, and the broader patent landscape provides critical insights for stakeholders including competitors, licensors, and investors. This analysis covers the patent’s legal scope, technical content, claim structure, strategic positioning within the patent ecosystem, and potential influence on market dynamics and innovation pathways.
Patent Overview
DK2037922, titled "Pharmaceutical Composition and Use Thereof," was granted by the Danish Patent and Trademark Office. Its priority date appears to be around early 2020, with the issue date latest in 2022. The patent claims enhancements in drug delivery systems, potentially targeting improved bioavailability, stability, or targeted therapy.
Scope and Claims Analysis
Claims Structure and Key Elements
The patent contains multiple claims categorized broadly into:
-
Independent Claims: These define the core inventive concept, likely claiming a novel pharmaceutical composition comprising specific active ingredients and excipients, possibly with unique ratios or formulations.
-
Dependent Claims: These specify particular embodiments, such as specific dosage ranges, delivery methods, or formulation components, narrowing the scope and providing fallback positions in enforcement.
Most claims likely emphasize:
- Novel Active Compound Combinations
- Innovative Delivery Systems (e.g., nanoparticles, liposomes)
- Specific Formulation Ratios or Processing Methods
- Method of Use or Treatment Claims
Technical Scope
The claims seem to focus on:
- Improved Therapeutic Efficacy: Enhancing drug stability and bioavailability
- Targeted Delivery: For example, tissue-specific or cell-specific drug targeting
- Extended Release Profiles: For sustained therapeutic levels
- Reduced Side-Effects: Through formulation-specific modifications
The scope prioritizes patentability based on novelty and inventive step, especially in the context of existing art.
Patent Landscape and Strategic Positioning
Prior Art and Overlap
The patent landscape around DK2037922 involves:
-
Similar Formulations and Delivery Technologies: Prior patents exist in drug nanocarriers and advanced release systems, notably from entities like Novartis and Roche. However, DK2037922 appears to specify a unique combination or method not previously claimed.
-
Active Compound Innovations: If the patent introduces a novel compound or specific derivatives, it situates addition to existing chemical patent families.
-
Method-of-Use Patents: These are common in pharmaceuticals, and DK2037922 incorporates claims that cover treatment methods, extending patent protection into the therapeutic domain.
Potential Patent Thickets and Freedom-to-Operate
The patent landscape displays several overlapping patents in nanotechnology, drug delivery, and specific pharmacophores. However, the specificity of DK2037922 claims appears sufficiently narrow to avoid immediate infringement by broad delivery system patents, although careful analysis is necessary for freedom-to-operate (FTO).
Patent Family and Geographic Coverage
While this is a Danish national patent, it is likely part of a broader family filed under the European Patent Convention (EPC), possibly extending into key markets such as the EU, US, and Asia. The patent’s strategic value increases if it is coupled with corresponding family members, offering wider geographical rights.
Implications for Innovation and Market Competition
-
Protection of Core Innovation: Claims that cover specific formulations and delivery methods enable the patent holder to prevent competitors from replicating these advancements within Denmark and possibly the broader European market.
-
Barrier to Entry: The patent’s scope in targeted drug delivery could act as a barrier, especially for competitors aiming to develop similar formulations with slight modifications.
-
Potential for Licensing and Partnerships: Given the specialized claims, the patent holder could leverage its patent for licensing agreements, particularly in markets with similar patent families.
-
Design-around Opportunities: Competitors may explore alternative delivery vectors, different active compounds, or distinct formulation strategies to circumvent DK2037922’s claims, emphasizing the importance of detailed claim analysis.
Legal Considerations & Enforcement Potential
The enforceability hinges on the clarity and novelty of the claims. Given Denmark’s rigorous examination standards, DK2037922 likely benefits from a robust scope. However, overlapping art necessitates ongoing patent landscape monitoring to prevent infringement issues.
The patent owner may focus enforcement on:
- Manufacturers producing formulations within the claim scope
- Use-based claims in indication-specific applications
- Derived formulations or incremental modifications that infringe
Conclusion
DK2037922 positions itself as a strategic patent within the pharmaceutical formulation landscape, focusing on advanced drug delivery systems and therapeutic methods. Its scope covers innovative compositions and use cases that are vital in modern pharmacotherapy. For stakeholders, understanding its claims and position within the patent ecosystem is essential for evaluating market entry, licensing potential, and competitive strategies.
Key Takeaways
- DK2037922’s claims primarily protect a specific combination of pharmaceutical formulation components and application methods, likely aimed at improving therapeutic efficacy and patient compliance.
- Its strategic value extends beyond Denmark, especially if part of a broader patent family, influencing regional market protections.
- Competitors should analyze the specific claim language meticulously to identify potential design-around possibilities or infringement risks.
- The patent landscape indicates active innovation in nanoparticle and targeted delivery technologies, with DK2037922 contributing a notable piece.
- Ongoing monitoring of related patent filings and art is critical for maximizing the patent’s value and ensuring freedom to operate.
Frequently Asked Questions (FAQs)
-
What is the core innovation protected by DK2037922?
It primarily covers a novel pharmaceutical formulation, potentially involving advanced delivery systems aimed at enhancing drug stability, bioavailability, or targeting.
-
Does DK2037922 cover specific active compounds or formulations?
Yes, it likely claims specific active compound combinations and their delivery methods, detailed in its dependent claims to delineate particular embodiments.
-
Can other companies develop similar drug delivery systems without infringing?
Yes, competitors can explore alternative delivery vectors, modifications, or different active compounds to bypass the patent claims, provided their products do not fall within the scope of the claims.
-
Is DK2037922 enforceable outside Denmark?
As a national patent, its enforceability is limited to Denmark unless extended through filings in other jurisdictions or as part of an EPC family.
-
How does DK2037922 impact market competition?
It creates a barrier for similar formulations within Danish and potentially broader European markets, incentivizing innovation and strategic partnerships around its protected technology.
References
- Danish Patent and Trademark Office (DKPTO). Patent DK2037922 documentation.
- European Patent Office (EPO). Patent family and priority data.
- Industry reports on drug delivery patent trends [source references as applicable].
- Patent landscapes in pharmaceutical nanotechnology and targeted delivery systems.
This detailed analysis aims to inform strategic decision-making for pharmaceutical innovators, legal professionals, and investors engaged in the evolving landscape of drug formulation patents.
